Status:
COMPLETED
Retrospective Evaluation of Lung Pathology in Subjects With COVID-19
Lead Sponsor:
Vicore Pharma AB
Conditions:
COVID-19
COVID-19 Pneumonia
Eligibility:
All Genders
18-70 years
Brief Summary
Non-interventional, retrospective, multi-center, follow-up study evaluating the effect of C21 on lung pathology in subjects previously hospitalised with COVID-19 and enrolled in the VP-C21-006 trial.
Detailed Description
The study will collect available HRCT scans obtained prior to, during treatment with C21 or placebo and up to 24 weeks after trial completion. HRCT scans will be assessed for ground glass opacity, re...
Eligibility Criteria
Inclusion
- Written informed consent
- Previously included in the VP-C21-006 trial and received at least one dose of investigational medicinal product (IMP)
- Available record of at least one HRCT performed within 24 weeks after completion of VP-C21-006.
Exclusion
- Participation in another interventional trial during the historical period covered by this study that could interfere with the study objectives or evaluation
Key Trial Info
Start Date :
July 7 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 23 2021
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT04878913
Start Date
July 7 2021
End Date
August 23 2021
Last Update
September 4 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medicine, Civil Hospital and B J Medical College
Ahmedabad, Gujarat, India, 380016
2
First Floor Clinical Research Department Rhythm Heart Institute
Vadodara, Gujarat, India, 290022
3
Department of Medicine, Government Medical College and Hospital
Nagpur, Maharashtra, India, 440003
4
Department of Medicine, Noble Hospitals Pvt. Ltd
Pune, Maharashtra, India